System Two

System Two is a biotechnology company focused on the discovery and development of small molecule therapeutics that target RNA. By leveraging advanced computational biology and high-throughput screening, the company aims to modulate RNA function to treat diseases that have been difficult to address with traditional protein-targeting approaches. Their platform integrates structural biology and machine learning to identify novel binding sites on complex RNA structures. System Two's current pipeline is focused on high-impact areas including oncology and rare genetic disorders. The company is positioned at the intersection of RNA biology and precision medicine, seeking to unlock the therapeutic potential of the non-coding genome.